Trump Admin yanks $700 MILLION in funding from Moderna, staving off another deadly mRNA jab and a combo H5N1/flu shot stab

Moderna, one of the main manufacturers of the deadliest vaccines ever crafted, was about to make more mRNA clot shots with the money they were granted from the insidious Biden Regime, until Trump put the brakes on it all. Contract canceled. Humans around the world can celebrate a little bit, for a little while, at least.

The agreement also allowed for up to five additional subtypes of pandemic influenza. A newer strain of the H5 virus has hit wild and domesticated flocks hard and spilled over to cows and supposedly in a few cases, humans, fueling concerns that it could acquire the ability to transmit between people. Can anyone say gain of function without coughing out the word Fauci?

Moderna CEO Stéphane Bancel said on Wednesday that the pulled funding “adds uncertainty” to the company’s bird flu program. It also comes at a critical juncture for Moderna, which is awaiting an FDA decision date for its next-generation COVID-19 shot mRNA-1283 at the end of this week and has been struggling to weather broader macro headwinds.

Recent moves from the Trump administration to hamstring mRNA vaccine research have raised concern across the scientific community. In Moderna’s case, despite data showing that its flu/COVID-19 vaccine outperformed current shots, the company elected to pull its regulatory application for the combo vaccine last week after consulting with the FDA.

The company at the time did not reveal the specific reason for withdrawing the application, only noting that it plans to resubmit “later this year,” when more efficacy data for a different flu vaccine becomes available. The combo vaccine, dubbed mRNA-1083, contains components of the H5 flu vaccine, as well as mRNA-1283, the COVID-19 vaccine under review.

Trump administration cancels $766 million Moderna contract for bird flu vaccine development

That’s right, the Trump administration has terminated a $766 million federal contract awarded to Moderna to develop an mRNA-based vaccine for avian influenza (H5N1), reversing a Biden-era agreement that aimed to prepare for another plandemic. The decision, announced this week, follows a U.S. Department of Health and Human Services (HHS) review concluding the project did not meet scientific and safety standards for continued funding.

The cancellation marks a sharp departure from the Trump administration’s previous support for rapid vaccine development under Operation Warp Speed during the COVID-19 pandemic.

The original 176 million contract, awarded in July 2024 by HHS’s Biomedical Advanced Research and Development Authority (BARDA), funded late?stage development of Moderna’s H5N1 vaccine with $590 million, bringing the total to $766 million. The deal also included provisions for up to five additional influenza subtypes, reflecting concerns over rising H5N1 cases in birds, cattle, and sporadic human infections.

However, HHS officials under the Trump administration determined the program lacked sufficient scientific merit to justify further investment. “After a comprehensive internal review, the agency concluded that the project did not meet the scientific standards or safety expectations required for continued federal funding,” an HHS spokesperson told Reuters.

Moderna CEO Stéphane Bancel acknowledged the financial setback, stating that the withdrawn funding “adds uncertainty” to the company’s bird flu program. The decision comes at a precarious time for Moderna, which faces declining demand for its COVID-19 vaccines and broader financial challenges.

The cancellation follows Moderna’s recent withdrawal of its application for a combined flu-COVID-19 vaccine, mRNA-1083, after discussions with the FDA. While the company cited plans to resubmit later with additional efficacy data, the delay underscores broader regulatory and market hurdles facing mRNA-based vaccines.

The H5N1 virus has caused significant outbreaks in poultry and dairy cows, raising fears of potential human-to-human transmission. Despite these concerns, the Trump administration’s decision signals skepticism toward preemptive mRNA vaccine investments—a stance that could reshape pandemic preparedness strategies moving forward.

The termination of Moderna’s contract reflects a broader reassessment of federal vaccine funding priorities under the Trump administration. While proponents argue the move ensures rigorous scientific scrutiny, critics warn it may leave the U.S. vulnerable in future outbreaks. As Moderna navigates financial and regulatory challenges, the debate over mRNA technology’s role in public health continues—with implications for both pandemic response and the biotech industry’s future.

Bookmark Vaccines.news to your favorite independent websites for updates on Trump canceling more funding for the experimental gene therapy injections that lead to turbo cancer and Long-Vax-Syndrome.

Sources for this article include:

Pandemic.news

NaturalNews.com

100percentfedup.com